Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00310895 · ClinicalTrials.gov registry record · Phase 1
Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies
A Phase 1 study, sponsored by Geron Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT00310895 is a Phase 1 study that has completed, run by Geron Corporation. The registered enrollment target is 85 participants.
The verdict
NCT00310895, a Phase 1 study, has completed, sponsored by Geron Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and the maximum tolerated dose of GRN163L administration in treating patients with refractory or relapsed solid tumor malignancies.
Interventions
- DRUG Imetelstat Sodium (GRN163L)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2006-03 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00310895
The ClinicalTrials.gov registry entry for NCT00310895 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Geron Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Imetelstat Sodium (GRN163L) is the first listed.
NCT00310895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00310895 about?
NCT00310895 is a clinical study titled "Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies". The purpose of this study is to determine the safety and the maximum tolerated dose of GRN163L administration in treating patients with refractory or relapsed solid tumor malignancies.
What is the current status of trial NCT00310895?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2006-03. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00310895?
The interventions under investigation include: Imetelstat Sodium (GRN163L) (DRUG).
Who is sponsoring clinical trial NCT00310895?
This trial is sponsored by Geron Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.